Article Details

Gilead, Arcus' Anti-TIGIT Combinations Show Survival Advantage Over Anti-PD1 ...

Retrieved on: 2022-12-21 03:51:13

Tags for this article:

Click the tags to see associated articles and topics

Gilead, Arcus' Anti-TIGIT Combinations Show Survival Advantage Over Anti-PD1 .... View article details on hiswai:

Excerpt

Gilead Sciences and Arcus Biosciences are testing therapies containing anti-TIGIT monoclonal antibody against the anti-PD-1 zimberelimab.

Article found on: www.geneonline.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up